AUTHOR=Guo Jinan , Liu Dale , Zhang Xuhui , Johnson Heather , Feng Xiaoyan , Zhang Heqiu , Wu Alan H. B. , Chen Lingwu , Fang Jiequn , Xiao Zhangang , Xiao Kefeng , Persson Jenny L. , Zou Chang 

TITLE=Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=8

YEAR=2020

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.597961

DOI=10.3389/fcell.2020.597961

ISSN=2296-634X

ABSTRACT=<p>One of the major features of prostate cancer (PCa) is its heterogeneity, which often leads to uncertainty in cancer diagnostics and unnecessary biopsies as well as overtreatment of the disease. Novel non-invasive tests using multiple biomarkers that can identify clinically high-risk cancer patients for immediate treatment and monitor patients with low-risk cancer for active surveillance are urgently needed to improve treatment decision and cancer management. In this study, we identified 14 promising biomarkers associated with PCa and tested the performance of these biomarkers on tissue specimens and pre-biopsy urinary sediments. These biomarkers showed differential gene expression in higher- and lower-risk PCa. The 14-Gene Panel urine test (<italic>PMP22</italic>, <italic>GOLM1</italic>, <italic>LMTK2</italic>, <italic>EZH2</italic>, <italic>GSTP1</italic>, <italic>PCA3</italic>, <italic>VEGFA</italic>, <italic>CST3</italic>, <italic>PTEN</italic>, <italic>PIP5K1A</italic>, <italic>CDK1</italic>, <italic>TMPRSS2</italic>, <italic>ANXA3</italic>, and <italic>CCND1</italic>) was assessed in two independent prospective and retrospective urine study cohorts and showed high diagnostic accuracy to identify higher-risk PCa patients with the need for treatment and lower-risk patients for surveillance. The AUC was 0.897 (95% CI 0.939–0.855) in the prospective cohort (<italic>n</italic> = 202), and AUC was 0.899 (95% CI 0.964–0.834) in the retrospective cohort (<italic>n</italic> = 97). In contrast, serum PSA and Gleason score had much lower accuracy in the same 202 patient cohorts [AUC was 0.821 (95% CI 0.879–0.763) for PSA and 0.860 (95% CI 0.910–0.810) for Gleason score]. In addition, the 14-Gene Panel was more accurate at risk stratification in a subgroup of patients with Gleason scores 6 and 7 in the prospective cohort (<italic>n</italic> = 132) with AUC of 0.923 (95% CI 0.968–0.878) than PSA [AUC of 0.773 (95% CI 0.852–0.794)] and Gleason score [AUC of 0.776 (95% CI 0.854–0.698)]. Furthermore, the 14-Gene Panel was found to be able to accurately distinguish PCa from benign prostate with AUC of 0.854 (95% CI 0.892–0.816) in a prospective urine study cohort (<italic>n</italic> = 393), while PSA had lower accuracy with AUC of 0.652 (95% CI 0.706–0.598). Taken together, the 14-Gene Panel urine test represents a promising non-invasive tool for detection of higher-risk PCa to aid treatment decision and lower-risk PCa for active surveillance.</p>